Screening — Total Revenue
Guardant Health Screening — Total Revenue increased by 18.4% to $41.59M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 632.6%, from $5.68M to $41.59M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful commercial scaling and market adoption of screening products, while a decrease may signal competitive pressure or challenges in clinical reimbursement and adoption rates.
Detailed definition
This metric represents the total gross revenue generated from a company's early-detection or screening-focused product p...
Peer comparison
Comparable to revenue from early-detection diagnostic platforms or preventative health screening services at other molecular diagnostics and biotechnology firms.
gh_segment_screening_total_revenueHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00M | $4.12M | $5.68M | $14.81M | $24.11M | $35.13M | $41.59M |
| QoQ Change | — | — | — | — | — | — | — | +310.9% | +37.8% | +160.9% | +62.8% | +45.7% | +18.4% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | >999% | +752.4% | +632.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Guardant Health's screening — total revenue?
- Guardant Health (GH) reported screening — total revenue of $41.59M in Q1 2026.
- How has Guardant Health's screening — total revenue changed year-over-year?
- Guardant Health's screening — total revenue increased by 632.6% year-over-year, from $5.68M to $41.59M.
- What does screening — total revenue mean?
- Total revenue generated from the sale of early-detection and cancer screening diagnostic tests.